Business
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
PALO ALTO, Calif. & NEW YORK, March 05, 2026--Evommune, Inc. (NYSE: EVMN) ("Evommune" or the "Company"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.
About this update from Evommune, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/b55e2c77f0cfa2a6fc79562ae7209b7c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xOPZgjBkKWyEGpFgXxwf9A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/b55e2c77f0cfa2a6fc79562ae7209b7c","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/NujNtervRtnHxMmMLulCjg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/b55e2c77f0cfa2a6fc79562ae7209b7c","width":1024,"height":512}},"lazy":false},{"type":"text","content":"– Reported positive top-line data from Phase 2a proof-of-concept (POC) trial of EVO301 in atopic dermatitis (AD)","length":112,"tagName":"p","attribs":{}},{"type":"text","content":"– EVO756 on track to report Phase 2b top-line data in chronic spontaneous urticaria (CSU) and AD in 2Q26 and 2H26, respectively","length":127,"tagName":"p","attribs":{}},{"type":"text","content":"– Strengthened balance sheet with $125 million private placement to support additional clinical milestones and extend runway through 2028","length":137,"tagName":"p","attribs":{}},{"type":"text","content":"PALO ALTO, Calif. & NEW YORK, March 05, 2026--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) ("Evommune" or the "Company"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.","length":402,"tagName":"p"},{"type":"text","content":""The positive top-line Phase 2a data for EVO301 marks an important milestone for Evommune and further validates IL-18 inhibition as a compelling approach for patients living with AD. We look forward to advancing the program forward and exploring an optimal dosing regimen for this potentially front-line biologic for AD," said Luis Peña, President and Chief Executive Officer at Evommune. "We’ve nearly completed patient enrollment in the EVO756 Phase 2b trial in CSU, and plan to share top-line data in the second quarter. Additionally, the EVO756 Phase 2b trial in AD ...